Introduction
Chronic heart failure (CHF) is predominantly a problem of the elderly. Estimates indicate that its prevalence increases dramatically with increasing age, from 0.9% in the 55-64 year age group to 17.4% in those aged ≥ 85 years. 1 Moreover, given their age, CHF patients typically suffer from comorbidities such as hypertension, coronary heart disease, diabetes mellitus, previous myocardial infarction (MI), renal failure and cardiac arrhythmia. Diabetes is probably the most important comorbidity for patients with CHF. Prognosis is poor in heart failure -50% of patients with symptomatic CHF (New York Heart Association [NYHA] class III) die within two years of diagnosis. 2 Not only is it important that the diagnoses of both the underlying causes of CHF and any concomitant diseases are accurate, but also the effects of drugs given to treat these co-morbidities must be considered, since they may interfere with treatments for CHF and impact negatively on prognosis. In diabetic CHF patients, drugs that have beneficial effects in diabetic nephropathy, or that are known to result in a lower incidence of new-onset dia-betes, such as angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors, should be given preferential consideration.
Case Report
A 70-year-old man with a recently treated anterior MI and a medical history of Type 2 diabetes mellitus, hypertension (for more than 10 years), gout and osteoarthritis in both knees with daily pain presented at the clinic with dyspnoea. His blood pressure at presentation was 150/90 mmHg and there was electrocardiographic evidence of left bundle branch block. The patient was in sinus rhythm (70 beats/minute) and the left ventricular ejection fraction (LVEF) was 30%. His medication on presentation at the clinic is summarised in Table 1 .
Treatment with the ARB candesartan was initiated, in addition to non-pharmacological management strategies recommended by current guidelines. 3 These measures resulted in marked Case report Table 1 Prescribed therapy before and after the clinic visit. Medications in italics were discontinued after rationalisation of therapy, in accordance with guideline recommendations 3 improvement in the dyspnoea. A low dose of digoxin (0.0625-0.125 mg) was also considered, based on evidence indicating that this may prove beneficial in elderly patients with symptomatic CHF. 4 In addition, the patient's existing therapy was rationalised in accordance with current guidelines. 3 The potassium salts, aspirin and clopidogrel were discontinued and the etoricoxib was replaced with opioid skin plasters (Table 1 ).
Initial therapy

Discussion and Conclusion
Treatment with an ARB is effective in optimising outcome in CHF patients with left ventricular systolic dysfunction who remain symptomatic despite established therapy with an ACE inhibitor and beta-blocker. This has been recognised in the recent revision of the European Society of Cardiology guidelines for the treatment of CHF. 3 Data from the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial clearly support this recommendation, demonstrating a significant reduction in cardiovascular death and CHF hospitalisation (by 15%, p=0.011) in those patients with low LVEF already receiving optimal heart failure therapy (including an ACE inhibitor) who were treated with candesartan compared with placebo. 5 Combined analysis of the CHARM low LVEF trials also showed a significant reduction in all-cause mortality (p=0.018) with candesartan compared with placebo. 6 Moreover, data from the CHARM-Overall programme 7 showed a significant reduction in the development of new diabetes with candesartan compared with placebo (by 22%, p=0.02). This is an important finding given the negative impact of diabetes on survival in CHF patients. 2 There is also a need to rationalise concomitant therapy in the CHF patient with multiple co-morbidities, in accordance with current guidelines. 3 Bearing this in mind, potassium supplements were withdrawn in this case as they are generally considered ineffective. 3 Potassium-sparing diuretics are also associated with an increased risk of hyperkalaemia and should be dosed carefully, with repeated determination of potassium levels. 3 There is little evidence that anti-thrombotic therapy modifies the risk of mortality due to vascular events in patients with CHF, therefore aspirin and clopidogrel were withdrawn. Current guidelines recommend that treatment with a nonsteroidal anti-inflammatory drug should be avoided in CHF patients. 3 The potential for increased bleeding complications with aspirin is another reason for withdrawal of treatment. 3 Furthermore, there is currently no evidence that aspirin is beneficial in the long-term management of the CHF patient; the benefits of aspirin on survival post-MI have been shown to be limited to the first month after the event. 8 In conclusion, this case report demonstrates the effectiveness of the ARB candesartan in an elderly patient with multiple co-morbidities who on presentation remained symptomatic despite established CHF therapy. The importance of rationalising concomitant therapy to minimise the potential for adverse drug interactions is emphasised. 
